(28 May 2021) Sotrovimab- 85% reduction in progression of Covid-19 in patients with mild/moderate disease
Early Covid-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab https://www.medrxiv.org/content/10.1101/2021.05.27.21257096v1 NCT04545060-In this preplanned interim analysis, which included an intent-to-treat population of 583 patients (sotrovimab, 291; placebo, 292), the primary efficacy endpoint was met. The risk of Covid-19 progression was significantly reduced… Continue reading "(28 May 2021) Sotrovimab- 85% reduction in progression of Covid-19 in patients with mild/moderate disease"